IQM Quantum Computers to Deliver Quantum Processing Units for the First Spanish Quantum Computer
IQM Quantum Computers (IQM), the European leader in quantum computers, announced today it has been selected to deliver quantum processing units for the first Spanish quantum computer to be installed at the Barcelona Supercomputing Center (BSC) and integrated into the MareNostrum 5 supercomputer, the most powerful in Spain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005345/en/
IQM Quantum Computer opened (Photo: Business Wire)
IQM is a member of the consortium led by Spanish companies Qilimanjaro Quantum Tech and GMV that was selected by Quantum Spain, an initiative promoted by the Ministry of Economic Affairs and Digital Transformation through the Secretary of State for Digitalisation and Artificial Intelligence (SEDIA) in December 2022, to build the first quantum computer for public use in Southern Europe.
Dr. Jan Goetz, CEO and Co-founder of IQM Quantum Computers, said, “This is a significant announcement for IQM. We have the right background and experience in developing quantum processors, computers, and national quantum ecosystems. We are looking forward to working with Qilimanjaro Quantum Tech and are delighted to be part of such a strong consortium and play an important role by providing quantum processing units for this notable project.”
The integration of the quantum computer into MareNostrum 5 will have the potential to significantly increase the impact of research and innovation by enabling solutions that complement the capabilities of existing supercomputers, which will be available to the research community, companies, and public organisations, and by strengthening technological and industrial development in Spain and the creation of highly qualified jobs.
“We are delighted to include the expertise of a great player such as IQM to support us developing this innovative system, that will be purely based on Spanish and European technology. We are sure that this will be a very fruitful collaboration and we are looking forward to be partnering with IQM,” said Victor Canivell, Co-founder and CEO of Qilimanjaro.
Jani Heikkinen, Head of Business Development and Country Manager for Spain, said, “This is another example of our European leadership, demonstrating our commitment to advancing the Spanish quantum ecosystem in collaboration with both public and private institutions. Through our office in Madrid, we are also able to provide the necessary support for this project.”
About IQM Quantum Computers
IQM is the pan-European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 240 employees with offices in Singapore, Paris, Madrid, Munich, and Espoo.
About Qilimanjaro
Qilimanjaro Quantum Tech is a deep-tech startup that brings practical applications of quantum computing to the market in a shorter timeframe than digital quantum computers, by using a different but complementary model of quantum computation: the analog model.
Qilimanjaro creates a coherent quantum annealer accessible via our cloud to run real-world applications such as optimisation tasks in the logistics, finance, and energy sector, among others, and quantum simulation of chemical and physical processes, very present in the materials and pharmaceutical research industries. Qilimanjaro aims at providing its clients with a faster, more accurate and sustainable solution to their computing problems.
It has closed significant customer contracts since its first year of operation and has become a key contributor to the European Commission’s AVaQus H2020 project on coherent quantum annealing. Qilimanjaro is a spin-off from the Barcelona Supercomputer Center (BSC), the University of Barcelona (UB) and the Institute of High-Energy Physics (IFAE).
About GMV
GMV is a privately owned technology business group founded in 1984 and trading on a worldwide scale in the following sectors: Space, Aeronautics, Defense and Security, Cybersecurity, Intelligent Transportation Systems, Automotive, Healthcare, Telecommunications and IT for government authorities and major corporations. In 2021, it had revenues of nearly 260 million euros. Working with a staff of over 3,000, the company now runs subsidiaries in Spain, USA, Germany, France, Poland, Portugal, Romania, UK, The Netherlands, Belgium, Malaysia, and Colombia. Seventy five percent of its turnover comes from international projects on all five continents. The company's growth strategy is based on continuous innovation, and it plows back 5% of its turnover into inhouse R&D. GMV has reached CMMI level 5, the world's most prestigious model in terms of enhancing an organization’s process capability, and it has numerous international patents.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005345/en/
Contact information
IQM Media Contact
Raghunath Koduvayur, Head of Marketing and Communications
Email: Raghunath@meetiqm.com
Mobile: +65 9353 0048
www.meetiqm.com
Media Contact
Alícia Labián Pagès, Corporate Operations Manager
Email: alicia.labian@qilimanjaro.tech
Mobile: +34 676 683 876
www.qilimanjaro.tech
For more information, please contact:
marketing@gmv.com
www.gmv.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release
RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict
IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release
IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating
Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release
Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla
Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m
Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom